Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia
- 30 April 1994
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 18 (4), 293-297
- https://doi.org/10.1016/0145-2126(94)90032-9
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.Journal of Clinical Oncology, 1992
- Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemiaBlood, 1992
- Idarubicin: A Second-Generation AnthracyclineDICP, 1991
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemiaBlood, 1991
- Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast CancerAmerican Journal of Clinical Oncology, 1990
- Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cellsCancer Chemotherapy and Pharmacology, 1990
- Pharmacokinetics of Daunorubicin and Doxorubicin in Plasma and Leukemic Cells from Patients with Acute Nonlymphoblastic LeukemiaTherapeutic Drug Monitoring, 1989
- High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivativeJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemiaCancer Letters, 1980